Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810

• DOI: 10.1186/s40425-016-0176-3
• Publication Date: 2016-10-22T07:54:52Z
• Authors: Gerald S. Falchook; Rom Leidner; Elizabeth Stankevich; Brian Piening; Carlo Bifulco; Israel Lowy; Matthew G. Fury
• Keywords: Immune checkpoint

Basal cell carcinoma (BCC) and cutaneous squamous (CSCC) share exposure to UV light as the dominant risk factor, these tumors therefore harbor high mutation burdens. In other malignancies, burden has been associated with clinical benefit from therapy antibodies directed against Programmed Death 1 (PD-1) immune checkpoint receptor. Highly mutated are more likely express immunogenic tumor neoantigens that attract effector T cells, which can be unleashed by blockade of PD-1 checkpoint.This report describes a patient metastatic BCC CSCC who were treated REGN2810, fully human anti-PD-1 monoclonal antibody, in an ongoing phase trial (NCT02383212). The experienced complete response (16+ months), partial (12+ months).These case reports suggest UV-associated skin cancers, beyond melanoma, sensitive blockade.Clinicaltrials.gov NCT02383212. Registered 2 February 2015.